Price
$54.85+13.14%Social Signal Score
Analyst Ratings
17 analystsRevenue
$265.71M+23.56%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ronald Lombardi
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 890
- Beta
- 0.33
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.56
Financials
Revenue
$265.71M+23.6%Net Income
$29.18M-9.4%EBITDA
$61.24M-20.6%Free Cash Flow
$67.08M+36.8%EPS (diluted)
$0.61+1.7%Shares Outstanding (diluted)
47.60M-10.8%Operating Expenses
$77.97MCash & Debt
$89.13MReturn of Capital
$0.00Revenue by Segment (annual)
$1.09BDividend per Share
$0.47Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $1.09B | $190.30M | $3.93 |
| 2025 | $1.14B | $214.60M | $4.32 |
| 2024 | $1.13B | $209.34M | $4.21 |
| 2023 | $1.13B | $-82.31M | $-1.65 |
| 2022 | $1.09B | $205.38M | $4.09 |
| 2021 | $943.37M | $164.68M | $3.28 |
| 2020 | $963.01M | $142.28M | $2.81 |
| 2019 | $975.78M | $-35.80M | $-0.69 |
| 2018 | $1.04B | $339.57M | $6.34 |
| 2017 | $882.06M | $69.39M | $1.31 |
| 2016 | $806.25M | $99.91M | $1.89 |
| 2015 | $714.62M | $78.26M | $1.50 |
| 2014 | $601.88M | $72.61M | $1.41 |
| 2013 | $623.60M | $65.50M | $1.29 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from PBH's reported EPS growth of 8.9% a year over 13 years.
- EPS in 5 years
- $6.01
- Implied price
- $90.22
- Return from $45.26
- 14.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $44.86 — -0.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 13 | 15 | 17 | 19 |
|---|---|---|---|---|---|
| -1.1% | -2.0% | 1.3% | 4.3% | 6.9% | 9.3% |
| 3.9% | 2.9% | 6.4% | 9.5% | 12.3% | 14.8% |
| 8.9% | 7.9% | 11.6% | 14.8% | 17.7% | 20.4% |
| 13.9% | 12.8% | 16.7% | 20.1% | 23.1% | 25.9% |
| 18.9% | 17.8% | 21.8% | 25.3% | 28.5% | 31.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
60-50.00%Social Signal Score
Mentions (9)
- Newsmarketbeat.com·3d ago·Negative
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.
View source ↗ - Newszacks.com·5d ago·Positive
PBH vs. NEOG: Which Stock Is the Better Value Option? Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript
View source ↗ - Newsprnewswire.com·35d ago·Negative
Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test National survey commissioned by DenTek, the #1 OTC dental guard brand for nighttime teeth grinding, finds nearly 8 in 10 football fans keep thinking about the game after it ends, with many reporting stress-related behaviors that extend into bedtime. NFL legends Ronde & Tiki Barber join DenTek to encourage fans to recognize when football stress may be affecting more than just game day.
View source ↗ - Newsfoxbusiness.com·45d ago·Negative
Nearly 40,000 eye drops recalled nationwide over possible contamination Prestige Brand Holdings is recalling 39,060 bottles of certain Clear Eyes drops over sterility concerns, according to a Food and Drug Administration report.
View source ↗ - Newsseekingalpha.com·48d ago·Positive
…tide, And 2026 Catalysts Amylyx Pharmaceuticals, Inc. is upgraded to Strong Buy after positive phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia [PBH]. Avexitide met its primary endpoint, achieving a 55% reduction in severe hypoglycemic events, with strong statistical significance and a favorable safety profile. Key catalysts include an NDA submission for avexitide in PBH by end-2026 and medical data presentation in 2026; expansion into long-acting GLP-1 antagonist AMX0318 is…
View source ↗ - Newszacks.com·54d ago·Negative
PBH or SYK: Which Is the Better Value Stock Right Now? Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newsmarketbeat.com·57d ago·Positive
Premium Brands Q2 Earnings Call Highlights Premium Brands TSE: PBH said its revised 2026 outlook reflects timing shifts in U.S. customer programs and the exit of a low-margin Ontario facility, rather than a deterioration in the company's underlying operating assumptions.
View source ↗ - Newsmarketbeat.com·58d ago·Positive
Prestige Consumer Healthcare Q1 Earnings Call Highlights Prestige Consumer Healthcare NYSE: PBH reported first-quarter fiscal 2027 revenue growth of 6.5%, supported by broad-based category strength, the initial contribution from its Breathe Right acquisition and retailer order timing. The company raised its reported full-year outlook to incorporate Breathe Right and LaCorium Health while maintaining its prior outlook for organic revenue growth.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $1.06 per share
Typical surprise +1.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.98 vs $0.89beat
- Wed, May 13$1.23 vs $1.39miss
- Thu, Feb 5$1.14 vs $1.16miss
- Thu, Nov 6$1.07 vs $0.97beat
- Thu, Aug 7$0.95 vs $1.01miss
- Thu, May 8$1.32 vs $1.30beat
Estimates and results for PBH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PBH officers and directors.
- Bought
- —
- Sold
- $2.5m
0 trades
13 trades
- Zerillo Jeffreysold
- Zerillo Jeffreysold
- Zerillo Jeffreysold
- Zerillo Jeffreysold
- Zerillo Jeffreysold
- Zerillo Jeffreysold
- Zerillo Jeffreysold
- Byom John Esold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Thomas Roland Tillissenate · NC · disclosed Feb 26, 2015 (13d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.